Bydureon BCise (Exenatide): Pen and Injection Uses

An Injectable Drug for Type 2 Diabetes

Close up on syringes for diabetes

digicomphoto / iStockphoto

Bydureon BCise (exenatide) is a once-weekly injectable medication prescribed to help manage blood sugar levels in people with type 2 diabetes. It belongs to a class of drugs known as GLP-1 RAs (also called incretin mimetics) that work by stimulating the secretion of glucagon-like peptide-1 receptor agonist (GLP-1 RA).

Bydureon BCise is only available with an auto-injection pen. Previously Bydureon came only as a preloaded pen that required you to first insert the needle into your skin, then press a button to deliver the medication. The original pen is no longer on the market and was replaced with Bydureon BCise auto-injection. Bydureon is not available in a generic.

GLP-1 RA drugs similar to Bydureon include:

  • Trulicity (dulaglutide)
  • Victoza (liraglutide)
  • Adlyxin (lixisenatide)
  • Ozempic (semaglutide)
  • Byetta (a short-acting form of exenatide)


Bydureon stimulates the pancreas to secrete insulin when it comes into contact with glucose. Because it is an extended-release medication, it needs to be injected only once a week at any time of day (as opposed to Byetta, which must be injected twice a day according to a strict schedule).

In clinical trials, Bydureon has been found to help to reduce A1C (a measurement of average blood glucose levels over three months) by about 1.6%. Exenatide has been found to have other benefits, including preservation of the function of beta cells, which are responsible for making insulin in the pancreas and promoting weight loss in people with type 2 diabetes.

Bydureon is not a substitute for insulin and should not be used in place of insulin for people who have type 1 diabetes or diabetic ketoacidosis.

Off-Label Uses

Although helpful for weight loss, Bydureon is not approved by the Food and Drug Administration (FDA) as a weight-loss drug. However, it has been used for that purpose, although rarely.

Before Taking

Bydureon typically is not prescribed as a first-line treatment for diabetes on its own. If it's used as initial treatment, the drug usually is prescribed alongside metformin and, in some cases, another treatment as well. Clinical guidelines from the American Diabetes Association recommend this approach for patients with high risk factors such as cardiovascular or kidney conditions.

Precautions and Contraindications

Before taking Bydureon, tell your provider if you have a history of gastrointestinal disease, pancreatitis, gallstones, alcoholism, or high blood triglyceride levels.

Bydureon is not intended for patients with type 1 diabetes. 

Animal studies found that Bydureon can cause harm to a fetus. For that reason, Bydureon should only be taken during pregnancy if it's clear that the benefits will be greater than the potential risks.

Anyone who becomes pregnant while taking Bydureon should let their healthcare provider know right away.

Because Bydureon has not been studied for pediatric use, it should not be prescribed for children or teenagers.


According to the manufacturer, the standard dosage for people with type 2 diabetes is one 2-milligram (mg) injection every seven days, on the same day each week, but at any time of day, with or without food. Check your prescription and talk to your healthcare provider to make sure you are taking the right dose for you.

  • Bydureon BCise is available as four single-dose auto injectors containing 2 mg of exenatide each (a 4-week supply). The Bydureon pen was discontinued in 2021.

How to Take and Store

Bydureon BCise injectors should be stored flat in the refrigerator. Before using one it must be brought to room temperature for 15 minutes and then shaken vigorously up and down for at least 15 seconds with the orange cap pointing up.

Bydureon should be injected subcutaneously (into the fatty tissue just beneath the surface of the skin—not into a muscle or vein). It can be administered at the same sites as insulin—the abdomen (two inches below the belly button), outer thighs, or the backs of the upper arms.

The same area can be injected each week, but the exact location should be changed. To ensure you get the full dose, hold the pen at the injection site for a full 15 seconds.

If you miss a dose of Bydureon, you can take it as long as your next scheduled dose is three or more days away. If your missed dose is within a one or two days of your next regularly scheduled dose, do not take your missed dose.

Side Effects

Bydureon injection side effects range from mild to severe.


Because Bydureon delays the flow of food from the stomach, the most common side effects include nausea and vomiting, which tend to diminish over time as the body gets used to the medication. Other common, albeit minor, side effects include itching and redness at the injection site.

If skin reactions progress to severe pain, swelling, blisters, an open wound, or a dark scab at the injection site, call your healthcare provider. In a small number of individuals, cellulitis (infection of the cellulite layer) or necrosis (tissue death) have developed at the injection site when using Bydureon. Surgical treatment may be necessary.

Other common side effects include:

  • Headaches
  • Decreased appetite
  • Fatigue
  • Diarrhea
  • Constipation


The following severe reactions are unlikely but may occur when using Bydureon and warrant immediate medical care:

  • Prolonged GI symptoms: Some people may experience diarrhea lasting for more than two days or constipation lasting longer than three days.
  • Acute pancreatitis: Symptoms of pancreatitis (inflammation of the pancreas) include persistent, severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting. If you experience these symptoms, stop taking Bydureon and call your healthcare provider.
  • Hypoglycemia: Symptoms of hypoglycemia (low blood glucose) include shaking, headache, sweating, fatigue, or increased heart rate. The risk of this complication increases if Bydureon is taken along with a sulfonylurea or insulin, in which case dosages of these medications may need to be adjusted.
  • Acute kidney injury: Taking Bydureon alone or in conjunction with other medications that directly affect the kidneys—especially angiotensin-converting enzyme inhibitors (ACEs), nonsteroidal anti-inflammatory drugs (NSAIDs), and diuretics—may impair the function of this organ. Symptoms include reduced urination, swelling in the legs or ankles, confusion, fatigue, and/or nausea. Discontinuing Bydureon and any additional medications may restore kidney function.
  • Immunogenicity: Some people develop antibodies to Bydureon while taking it, which typically is characterized by a worsening glycemic response. If this happens to you, stop taking the drug and consult your healthcare provider.
  • Hypersensitivity: Some may also experience severe allergic reactions to exenatide, such as anaphylaxis or angioedema (swelling under the skin).

Warnings and Interactions

Bydureon comes with an FDA-mandated black box warning about the risk of thyroid-C cell tumors associated with taking the drug as seen in animal studies. It is not known if taking Bydureon causes thyroid cancer in humans.

Even so, Bydureon is contraindicated for people with a personal or family history of medullary thyroid cancer (MTC) as well as for those with multiple endocrine neoplasia syndrome type 2 (MEN 2). People with a sensitivity to exenatide or to any product components should also not take Bydureon.

Bydureon slows the rate at which food is emptied from the stomach, and so any medications taken by mouth, such as Tylenol (acetaminophen), may not be absorbed as quickly as they should. 

According to the manufacturer, Bydureon has not been studied with warfarin, but people taking warfarin in conjunction with Bydureon should have their international normalized ratio (INR) levels checked more frequently (a test measuring blood clotting time) in case of potential interaction.

Don't drink alcohol or use recreational drugs while taking Bydureon, as they have the potential to reduce your blood sugar and cause hypoglycemia.

Consult your healthcare provider before stopping Bydureon, as you may need a weaning schedule to prevent blood glucose management repercussions.

Frequently Asked Questions

  • Why was Bydureon discontinued?

    Bydureon injectable pens were discontinued in 2021 and replaced with Bydureon BCise. The medication is the same.

  • What is the difference between Bydureon and Bydureon BCise?

    The delivery devices. Bydureon BCise is an auto-injector you press against the skin.

    The original Bydureon (now discontinued) was a pre-loaded pen with a disposable needle you inserted into the skin before pushing a button to deliver the dose.

    Bydureon BCise also requires less mixing (15 taps versus 80) than the original.

  • Is Bydureon considered insulin?

    No, Bydureon is not insulin. It is a GLP-1 receptor agonist, a medication that stimulates the pancreas to secrete more insulin.

  • Are Trulicity and Bydureon the same?

    Trulicity and Bydureon are similar, but they are not the same. Both are once-weekly GLP-1 receptor agonists used to treat type 2 diabetes. Bydureon is the drug exenatide. Trulicity is dulaglutide.

  • Is Bydureon the same as Ozempic?

    No, Ozempic is the drug semaglutide. Bydureon is the drug exenatide. Both are once-weekly GLP-1 receptor agonists used to treat type 2 diabetes.

  • Is Bydureon used for weight loss?

    Yes and no. Weight loss is not an FDA-approved use of Bydureon. However, weight loss is a side effect of Bydureon and other GLP-1 receptor agonists. People with type 2 diabetes who take this class of drug lose about 5 pounds over six months of treatment.

    The only GLP-1 receptor agonist FDA-approved to be marketed for weight loss is Wegovy (semaglutide).

8 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. U.S. Food and Drug Administration. Bydureon (exenatide extended-release) for injectable suspension.

  2. Scheen AJ. Bydureon: First once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014;69(4):214-9.

  3. Cersosimo E, Solis-Herrera C, Trautmann ME, et al. Assessment of pancreatic β-cell function: Review of methods and clinical applicationsCurr Diabetes Rev. 2014;10(1):2-42. doi:10.2174/1573399810666140214093600

  4. Fakhoury WKH, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. 2010;86(1):44-57. doi:10.1159/000314690

  5. U.S. Food and Drug Administration. Bydureon.

  6. Hendricks EJ. Off-label drugs for weight loss. Diabetes Metab Syndr Obes. 2017; 10: 223–234. doi:10.2147/DMSO.S95299

  7. Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical GuidelineAnn Intern Med. 2020;173(10):813-821. doi:10.7326/M20-2470

  8. Bydureon BCise. How to use.

Additional Reading

By Barbie Cervoni MS, RD, CDCES, CDN
Barbie Cervoni MS, RD, CDCES, CDN, is a registered dietitian and certified diabetes care and education specialist.